These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 27129796

  • 1. Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients.
    Depreter B, Stove V, Delanghe J.
    Clin Biochem; 2016 Dec; 49(18):1390-1395. PubMed ID: 27129796
    [Abstract] [Full Text] [Related]

  • 2. Acid freezes uricolysis in addition to glycolysis: Utility of fluoride-EDTA-citrate tube in the measurement of uric acid for patients administered rasburicase.
    Kalaria T, Fenn J, Whitmill R, Ford C, Gama R.
    Ann Clin Biochem; 2022 May; 59(3):178-182. PubMed ID: 34989247
    [Abstract] [Full Text] [Related]

  • 3. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN, Shanholtz CB, Thompson JL.
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW, Lo M, Crank CW.
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R, Sinha S, Nirni SS, Patil SG, Pedapenki RM.
    Indian J Cancer; 2014 Sep; 51(2):180-3. PubMed ID: 25104205
    [Abstract] [Full Text] [Related]

  • 6. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD, Dinh BC.
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [Abstract] [Full Text] [Related]

  • 7. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS, Thompson S, Tangirala K, Eaddy MT.
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [Abstract] [Full Text] [Related]

  • 8. Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
    Kimura K, Kanehira N, Takayanagi R, Minohara H, Homma M, Yamada Y.
    Biol Pharm Bull; 2016 Mar; 39(5):705-11. PubMed ID: 27150142
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
    Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R, Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma.
    J Clin Oncol; 2003 Dec 01; 21(23):4402-6. PubMed ID: 14581437
    [Abstract] [Full Text] [Related]

  • 10. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M, Redd R, Ni J, Stone RM, DeAngelo DJ, McDonnell AM.
    J Oncol Pharm Pract; 2019 Sep 01; 25(6):1349-1356. PubMed ID: 30111244
    [Abstract] [Full Text] [Related]

  • 11. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD, Ajiboye VO.
    J Oncol Pharm Pract; 2010 Sep 01; 16(3):205-13. PubMed ID: 19923162
    [Abstract] [Full Text] [Related]

  • 12. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
    Campara M, Shord SS, Haaf CM.
    J Clin Pharm Ther; 2009 Apr 01; 34(2):207-13. PubMed ID: 19250141
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
    Cammalleri L, Malaguarnera M.
    Int J Med Sci; 2007 Mar 02; 4(2):83-93. PubMed ID: 17396159
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A, Lathon SC, Boehmer L, Augustin KM, Butler SK, Westervelt P.
    Pharmacotherapy; 2013 Mar 02; 33(3):295-303. PubMed ID: 23456733
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.